INDSWFTLAB — IND Swift Laboratories Share Price
0.000.00%
Last trade - 00:00- IN₹4.56bn
- IN₹343.75m
- IN₹12.81bn
- 43
- 93
- 13
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.48 | ||
| Price to Tang. Book | 0.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.09 | ||
| EV to EBITDA | 0.15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 40.41% | ||
| Return on Equity | 40.65% | ||
| Operating Margin | 92.52% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 7,796.43 | 8,913.44 | 10,387.34 | 12,073.1 | 12,809 | n/a | n/a | 11.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +123.46 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ind-Swift Laboratories Limited is an India-based company. The Company is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company’s products include APIs and Impurities. The Company offers reference standards and impurities for various APIs under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for quick and reliable supply. The Company offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories. Its products include Clarithromycin, Clarithromycin Coated Granules, Ezetimibe, Pazopanib HCl, Ranolazine, Aripiprazole, Letrozole, and Imatinib Mesylate, others.
Directors
- Sanjeev Mehta NEC (57)
- Sahil Munjal PRE
- Sunil Deshmukh CEO
- N. Munjal VCH (69)
- N. Bansal CFO
- Vikas Narendra CEX
- Lalit Wadhwa COO
- Rajesh Naik SVP
- Pardeep Verma CCO
- Uresh Raval VPR
- Rakesh Bahuguna VPR
- Sandeep Singh VPR
- Ajay Srivastava VPR
- Saranjai Tyagi VPR
- Himanshu Jain MDR (31)
- Rishav Mehta EDR
- Vijay Kumar DMK
- Subodh Gupta OTH
- G. Sharma OTH
- Satyendra Singh DRC
- Vikrant Mehta NED (56)
- Gopal Munjal NED (53)
- Jagvir Ahiuwaiia IND (69)
- Neerja Chathley IND
- Preetika Chaubey IND
- Rajinder Gupta IND
- Prabhat Khurana IND
- S. Sharma IND
- Ashwani Vig IND
- J. Kakkar NID (76)
- K. M. S. Nambiar NID (71)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 4th, 1995
- Public Since
- March 15th, 2002
- No. of Shareholders
- 22,438
- No. of Employees
- 47
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 60,618,860
- Address
- SCO 850, CHANDIGARH, 160101
- Web
- https://www.indswiftlabs.com/
- Phone
- +91 1725061850
- Contact
- Pardeep Verma
- Auditors
- Avishkar Singhal & Associates
Upcoming Events for INDSWFTLAB
Q1 2026 IND Swift Laboratories Ltd Earnings Release
Ind Swift Laboratories Ltd Annual Shareholders Meeting
Similar to INDSWFTLAB
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the IND Swift Laboratories share price?
As of Today at 21:17 UTC, shares in IND Swift Laboratories are trading at IN₹80.51. This share price information is delayed by 15 minutes.
How has the IND Swift Laboratories share price performed this year?
Shares in IND Swift Laboratories last closed at IN₹80.51 and the price had moved by -35.26% over the past 365 days. In terms of relative price strength the IND Swift Laboratories share price has underperformed the S&P BSE 100 Index by -39.01% over the past year.
What are the analyst and broker recommendations for IND Swift Laboratories?
There is no consensus recommendation for this security.
Find out moreWhat is the IND Swift Laboratories dividend yield?
IND Swift Laboratories does not currently pay a dividend.
Does IND Swift Laboratories pay a dividend?
IND Swift Laboratories does not currently pay a dividend.
When does IND Swift Laboratories next pay dividends?
IND Swift Laboratories does not currently pay a dividend.
How do I buy IND Swift Laboratories shares?
To buy shares in IND Swift Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IND Swift Laboratories?
As of the previous close price of IN₹80.51, shares in IND Swift Laboratories had a market capitalisation of IN₹4.56bn.
Where are IND Swift Laboratories shares listed?
Here are the trading details for IND Swift Laboratories:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: INDSWFTLAB
What kind of share is IND Swift Laboratories?
Based on an overall assessment of its quality, value and momentum IND Swift Laboratories is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IND Swift Laboratories share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the IND Swift Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IND Swift Laboratories. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -28.77%.
As of the last closing price of IN₹80.51, shares in IND Swift Laboratories were trading -30.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IND Swift Laboratories PE Ratio?
The IND Swift Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹80.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IND Swift Laboratories?
IND Swift Laboratories' management team is headed by:
- Sanjeev Mehta - NEC
- Sahil Munjal - PRE
- Sunil Deshmukh - CEO
- N. Munjal - VCH
- N. Bansal - CFO
- Vikas Narendra - CEX
- Lalit Wadhwa - COO
- Rajesh Naik - SVP
- Pardeep Verma - CCO
- Uresh Raval - VPR
- Rakesh Bahuguna - VPR
- Sandeep Singh - VPR
- Ajay Srivastava - VPR
- Saranjai Tyagi - VPR
- Himanshu Jain - MDR
- Rishav Mehta - EDR
- Vijay Kumar - DMK
- Subodh Gupta - OTH
- G. Sharma - OTH
- Satyendra Singh - DRC
- Vikrant Mehta - NED
- Gopal Munjal - NED
- Jagvir Ahiuwaiia - IND
- Neerja Chathley - IND
- Preetika Chaubey - IND
- Rajinder Gupta - IND
- Prabhat Khurana - IND
- S. Sharma - IND
- Ashwani Vig - IND
- J. Kakkar - NID
- K. M. S. Nambiar - NID